ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,000 | -57.9% | 6,122 | -40.2% | 0.00% | -100.0% |
| Q2 2023 | $14,235 | -74.0% | 10,241 | -70.2% | 0.00% | -75.0% |
| Q1 2023 | $54,729 | -70.3% | 34,421 | -6.7% | 0.00% | -73.3% |
| Q4 2021 | $184,000 | +54.6% | 36,904 | +272.4% | 0.02% | +66.7% |
| Q3 2021 | $119,000 | +466.7% | 9,909 | +1334.0% | 0.01% | -35.7% |
| Q1 2020 | $21,000 | -78.8% | 691 | -69.3% | 0.01% | +100.0% |
| Q3 2018 | $99,000 | -13.2% | 2,250 | +41.7% | 0.01% | -30.0% |
| Q1 2018 | $114,000 | +395.7% | 1,588 | +348.6% | 0.01% | +400.0% |
| Q4 2017 | $23,000 | -36.1% | 354 | -50.9% | 0.00% | -33.3% |
| Q3 2017 | $36,000 | -72.7% | 721 | -74.7% | 0.00% | -75.0% |
| Q2 2017 | $132,000 | -16.5% | 2,853 | -36.5% | 0.01% | -29.4% |
| Q1 2017 | $158,000 | +129.0% | 4,493 | +44.1% | 0.02% | +41.7% |
| Q4 2015 | $69,000 | -62.9% | 3,118 | +54.7% | 0.01% | -73.9% |
| Q1 2015 | $186,000 | – | 2,015 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $59,618,000 | 21.09% |
| Bellevue Group AG | 4,519,164 | $95,580,000 | 0.93% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $36,234,000 | 0.84% |
| Rhenman & Partners Asset Management AB | 572,267 | $12,103,000 | 0.82% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 64,434 | $1,363,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $10,575,000 | 0.37% |
| EMC Capital Management | 27,566 | $583,000 | 0.33% |
| WASATCH ADVISORS LP | 3,766,935 | $79,671,000 | 0.32% |
| Avidity Partners Management LP | 400,000 | $8,460,000 | 0.23% |
| Cinctive Capital Management LP | 186,170 | $3,937,000 | 0.18% |